COVID-19: androgen deprivation therapy may have protective effect

  • Montopoli M & et al.
  • Ann Oncol
  • 6 mai 2020

  • Par Deepa Koli
  • Résumés d'articles
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • Patients with cancer have an increased risk for SARS-CoV-2 infection vs those without. 
  • Patients with prostate cancer receiving androgen-deprivation therapy (ADT) show lower risk for infection vs those who did not receive ADT or with any other type of cancer.

Why this matters

  • These authors call for further exploration of the protective effect of ADT against COVID-19.

Study design

  • Study of 4532 SARS-CoV-2-positive male patients with or without cancer. 
  • Funding: Supported by grant to author from European Research Council; Swiss Cancer League; Swiss National Science Foundation; Prostate Cancer Foundation; Italian Association for Cancer Research.

Key results

  • 68% of patients were
  • 9.5% of patients had cancer, and 2.6% had prostate cancer.
  • Patients with cancer had a higher risk for SARS-CoV-2 infection vs those without:
    • OR, 1.79 (95% CI, 1.62-1.98).
  • Compared with patients with prostate cancer receiving ADT, the risk for SARS-CoV-2 was significantly higher in:
    • Patients with prostate cancer who did not receive ADT: OR, 4.05 (95% CI, 1.55-10.59).
    • Patients with any other type of cancer: OR, 5.17 (95% CI, 2.02-13.40).

Limitations

  • Observational.